Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma.
|
31241175 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We studied the association of immunohistochemical expression of hypoxia inducible factor-1 alpha (HIF-1α), telomerase reverse transcriptase (TERT), isocitrate dehydrogenase 1 (IDH1) and tumor protein p53 with overall survival (OS) in glioblastoma patients uniformly treated by standard of care, with adequate follow-up.
|
31258744 |
2019 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To evaluate the frequency of MGMT methylation status in a single institute series of 134 GBMs and correlate it with clinical (age, sex, location, survival) and other molecular parameters [such as p53 expression, alpha thalassemia/mental retardation syndrome X-linked (ATRX) expression, isocitrate dehydrogenase (IDH) 1R132H mutation, and epidermal growth factor receptor (EGFR) gene amplification].
|
30038102 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We found that HR indeed regulates p53 target genes, including those implicated in cell cycle progression and apoptosis in the GBM-derived U87 cell line, and restoring HR expression triggered G2/M arrest and apoptosis.
|
30191601 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our recent study indicated that TSN has anti-cancer effect in glioblastoma through induction of estrogen receptor β (ERβ) and p53.
|
29629572 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma.
|
30940658 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Alkylaminophenol Induces G1/S Phase Cell Cycle Arrest in Glioblastoma Cells Through p53 and Cyclin-Dependent Kinase Signaling Pathway.
|
31001122 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To determine whether there is a threshold for the TMZ-induced DNA damage response and exploring the factors regulating the switch between p53 dependent survival and death, the glioblastoma lines LN-229 (deficient in MGMT) and LN-229MGMT (stably transfected with MGMT) were exposed to different doses of TMZ. p53 protein expression and phosphorylation levels of p-p53ser15 and p-p53ser46 were determined by Western blotting.
|
30925722 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Impairment of IMPDH2 activity triggers nucleolar stress and growth arrest of glioblastoma cells even in the absence of functional p53.
|
31371825 |
2019 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Role of asparagine endopeptidase in mediating wild-type p53 inactivation of glioblastoma.
|
31400201 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.
|
31081046 |
2019 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated the role of MTBP in the biology of TP53-wildtype (TP53wt) GBMs.
|
31534534 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
More than 1700 proteins were quantified, and bioinformatics predicted activations of MYC, NFE2L2, FN1, and TGFβ1 and inhibition of TP53 in GBM-EV stimulated astrocytes that were then confirmed by qPCR.
|
30353492 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, biotinylated PAMAM G3 dendrimers substituted with the recognized anticancer agents cyclooxygenase-2 (COX-2) inhibitor celecoxib and peroxisome proliferator-activated receptor γ (PPARγ) agonist Fmoc-L-Leucine (G3-BCL) were tested in vitro on human cell lines with different p53 status: glioblastoma (U-118 MG), normal fibroblasts (BJ) and immortalized keratinocytes (HaCaT).
|
31652556 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Effects of RG7388 and radiotherapy were analyzed in p53 wild-type glioblastoma cell lines and glioma-initiating cells.
|
30274984 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Quantitative morphological tumor characteristics on post-contrast T1-weighted MRI can to a certain degree provide insights regarding Ki67 and p53 status in patients with glioblastoma.
|
31020343 |
2019 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The Kaplan-Meier survival plot illustrated poor survival in glioblastoma patients with over-expressed LINC-ROR ( P=0.010) and down-regulated p53 ( P=0.002).
|
30852975 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This antagonism results in increased p53 activity and can also re-activates the p53 pathway and resensitize the glioblastoma cells to apoptosis.
|
30656973 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFRα Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma.
|
30594071 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We suppose that performing a standard molecular analysis (IDH, EGFR, p53 and Ki67) is not sufficient to predict the behavior of a GBM in regards to overall survival (OS), nor to provide a deeper understanding of the meaning of the different genetic alterations in the DNA of cancer cells.
|
31801254 |
2019 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
BRCA1 identified as a modulator of temozolomide resistance in P53 wild-type GBM using a high-throughput shRNA-based synthetic lethality screening.
|
31815044 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We used CRN2 knock-out mice for analyses as well as for crossbreeding with a Tp53/Pten knock-out glioblastoma mouse model.
|
31677819 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Correlation analysis of expressions of PTEN and p53 with the value obtained by magnetic resonance spectroscopy and apparent diffusion coefficient in the tumor and the tumor-adjacent area in magnetic resonance imaging for glioblastoma.
|
29745082 |
2019 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mean Ki-67 labeling index was 29% (range, 1.5%-80%). p53 mutation was present in 20/36 GBs (55%), whereas OLIG2 expression was positive in 29/36 GBs (80.5%).
|
31003026 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Specifically, targeting cellular pathways frequently altered in glioblastoma, such as the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), the p53 and the retinoblastoma (RB) pathways, or epidermal growth factor receptor (EGFR) gene amplification or mutation, have failed to improve outcome, likely because of redundant compensatory mechanisms, insufficient target coverage related in part to the blood brain barrier, or poor tolerability and safety.
|
31541850 |
2019 |